We have evaluated over 1,200 human tumors and inflammatory diseases (including 146 colon cancers and 44 adenomatous polyps; and large sample sizes of small intestinal, prostate, ovary lung, stomach, and breast carcinomas) to define the prevalence of NOX1 expression in these diseases at a pre-defined level of statistical certainty. Here, NOX1 is linked to breast carcinoma.